Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:ALGSNASDAQ:MRNSNASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.50+3.7%$0.55$0.40▼$1.07$10.38M2.2249,391 shs258,441 shsALGSAligos Therapeutics$7.21+1.0%$6.18$3.76▼$46.80$44.08M2.69211,372 shs87,518 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.82 million shs260 shsSRZNSurrozen$9.02+8.0%$8.89$5.90▼$18.17$77.23M0.5722,083 shs23,827 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+3.69%-1.07%-33.32%-2.00%-40.84%ALGSAligos Therapeutics+0.98%-4.50%+24.53%-20.94%-27.65%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-56.42%SRZNSurrozen+8.02%-9.71%+14.32%-18.07%-14.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.9073 of 5 stars0.04.00.00.01.41.70.6ALGSAligos Therapeutics4.1684 of 5 stars3.53.00.04.82.71.70.0MRNSMarinus Pharmaceuticals2.2418 of 5 stars3.20.00.04.20.61.70.6SRZNSurrozen3.1711 of 5 stars3.53.00.00.03.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AALGSAligos Therapeutics 3.00Buy$70.00870.87% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideSRZNSurrozen 3.00Buy$38.50326.83% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, ALGS, SRZN, and MRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/2/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K519.00N/AN/A$1.10 per share0.45ALGSAligos Therapeutics$3.94M11.18N/AN/A($7.50) per share-0.96MRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77SRZNSurrozen$10.65M7.25N/AN/A($6.55) per share-1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$1.29N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)ALGSAligos Therapeutics-$131.21M-$17.51N/AN/AN/A-1,628.75%14.67%7.19%8/5/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)SRZNSurrozen-$63.56M-$24.96N/AN/AN/AN/A-842.90%-71.32%8/11/2025 (Estimated)Latest AIMD, ALGS, SRZN, and MRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million5/9/2025Q1 2025SRZNSurrozen-$1.09-$3.13-$2.04-$7.43N/A$0.98 million5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million3/31/2025Q4 2024SRZNSurrozen-$2.54-$9.10-$6.56-$9.10N/A$0.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AALGSAligos TherapeuticsN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.842.001.91ALGSAligos TherapeuticsN/A7.567.56MRNSMarinus PharmaceuticalsN/A1.661.47SRZNSurrozenN/A10.0210.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AALGSAligos Therapeutics60.43%MRNSMarinus Pharmaceuticals98.80%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%ALGSAligos Therapeutics4.80%MRNSMarinus Pharmaceuticals5.46%SRZNSurrozen45.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4020.76 million18.61 millionNot OptionableALGSAligos Therapeutics906.11 million5.82 millionNo DataMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableSRZNSurrozen808.56 million4.69 millionNot OptionableAIMD, ALGS, SRZN, and MRNS HeadlinesRecent News About These CompaniesSurrozen (NASDAQ:SRZN) Shares Down 1.4% - What's Next?June 25 at 2:41 AM | marketbeat.comSurrozen, Inc. (NASDAQ:SRZN) Short Interest Down 16.0% in MayJune 3, 2025 | marketbeat.comDown -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a TurnaroundMay 16, 2025 | zacks.comSurrozen secures patent for tissue repair technologyMay 15, 2025 | investing.comSurrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayMay 14, 2025 | globenewswire.comSurrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 10, 2025 | finanznachrichten.deSurrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comSurrozen files to sell 5.21M shares of common stock for holdersApril 25, 2025 | markets.businessinsider.comSurrozen reports FY24 EPS ($21.67) vs. ($21.33) last yearApril 2, 2025 | markets.businessinsider.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comSurrozen Focuses on Ophthalmology Amid Financial ChallengesApril 1, 2025 | tipranks.comSurrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 31, 2025 | globenewswire.comSurrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 SharesMarch 29, 2025 | insidertrades.comSurrozen to focus Wnt expertise, technologies on ophthalmology programsMarch 27, 2025 | markets.businessinsider.comSurrozen to discontinue development of SZN-043 in alcohol associated hepatitisMarch 26, 2025 | markets.businessinsider.comSurrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 DevelopmentMarch 24, 2025 | quiverquant.comQSurrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye DiseasesMarch 24, 2025 | globenewswire.comSurrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News SummaryJanuary 30, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy RecommendationJanuary 30, 2025 | msn.comH.C. Wainwright sets $32 target on Surrozen stock with Buy ratingJanuary 30, 2025 | msn.com(SRZN) Trading AdviceJanuary 30, 2025 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, ALGS, SRZN, and MRNS Company DescriptionsAinos NASDAQ:AIMD$0.50 +0.02 (+3.69%) As of 06/27/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Aligos Therapeutics NASDAQ:ALGS$7.21 +0.07 (+0.98%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$7.02 -0.19 (-2.69%) As of 06/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Surrozen NASDAQ:SRZN$9.02 +0.67 (+8.02%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$9.00 -0.02 (-0.22%) As of 06/27/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
